Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > REGULATORY
REGULATORY
- AMED to Allocate 820 Million Yen for Measures against Antimicrobial Resistance
May 27, 2016
- Clinical Research Bill Unlikely to Clear Diet in Current Session
May 27, 2016
- MHLW to Request Budgets to Promote Venture Companies in Response to Growth Strategy
May 26, 2016
- Pemphigoid Added to List of Clinically Significant Adverse Reactions for DPP-4 Inhibitors: Safety Bulletin
May 26, 2016
- MHLW Working Group Urges Govt to Push NTD Drug Development at Mie Summit
May 25, 2016
- MHLW to Begin Discussions this Fiscal Year on Regulation of Plasma Exports
May 25, 2016
- AZ’s Ticagrelor, Boehringer’s Triple Combo Added to MHLW Panel’s Review Agenda for May 27
May 24, 2016
- Takecab-Contained Blister Packs for H. pylori Eradication, Other Products to Join NHI Price List on May 25
May 24, 2016
- MHLW OKs Add’l Indications for Avastin, Other Drugs
May 24, 2016
- MHLW’s Expanded Development Request Scheme Gets Underway
May 23, 2016
- Lecture Fees Paid “Purely as Compensation” Would Not Be Subject to Regulation under New Clinical Research Bill: Health Policy Bureau Chief
May 23, 2016
- Govt’s Draft Economic Growth Strategy Embraces Use of Big Data by PMDA
May 20, 2016
- Deregulation Panel Calls for Revisiting Plasma Export Restrictions, Wants Conclusion by FY2018
May 20, 2016
- Clinical Research Bill to Make It Easier for Companies to Provide Unapproved Drugs for Clinical Programs: LDP Lawmaker
May 20, 2016
- Council Determines Parathyroid Hormone Preparation for Hypoparathyroidism Has High Unmet Medical Need
May 20, 2016
- MHLW Raises Caution for Use of Harvoni, 7 Other Hep C Drugs in HBV Carriers
May 19, 2016
- Clinical Research Bill to Enter Diet Deliberations on May 20, Might Be Enacted June 1
May 19, 2016
- MOF Panel Recommends Full Rollout of Cost-Effective Evaluations
May 19, 2016
- LDP Bigwig Questions Costly Meds Reimbursement without Politicians’ Input
May 19, 2016
- Draft of Govt’s Economic, Fiscal Policy Blueprint Mentions “Optimal Use of Innovative Drugs”
May 19, 2016
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…